|
Dr. Dunbar joined Targacept in June 2001 from Bristol-Myers Squibb, where he was Vice President, Neuroscience Clinical Research and Development. In this position, which he held since January 1997, Dr. Dunbar was responsible for the worldwide clinical development of all neuroscience drugs, from Phase I through Phase IV. He has extensive experience in designing and overseeing clinical trials and evaluating product safety and effectiveness. While at Bristol-Myers Squibb, he had a leadership role in the in-licensing activities and clinical development plans for Abilify (aripiprazole), an antipsychotic drug.
From 1990 to 1996, Dr. Dunbar served as Director and Vice President of Clinical Research and Development for SmithKline Beecham, where he oversaw the clinical development of a portfolio of eight drugs. He successfully led the effort to expand the approved usage of Paxil (paroxetine), a drug for depression, to include indications for obsessive compulsive disorder, panic disorder and social phobia. He and his team were also responsible for the milestone trials of ReQuip (ropinirole), a dopamine agonist, as first line therapy in Parkinson’s disease.
Dr. Dunbar also held positions of increasing responsibility at Organon, Wyeth Research and Beecham Pharmaceuticals.
Dr. Dunbar received his medical degree in 1972 from London University, with honors in Pharmacology, and completed internships at Guys Hospital Group, Princess Alexandra Hospital and Maudsley & Bethlem Hospital, all in the U.K. He is a Fellow of the Royal College of Psychiatrists and a Fellow of the Faculty of Pharmaceutical Physicians (UK). He began his career in the pharmaceutical industry in 1979 and has over 50 papers in peer-reviewed journals.
As Vice President, Clinical Development and Regulatory Affairs, Dr. Dunbar is responsible for building a best-in-class organization that undertakes clinical development and regulatory submissions, as a well-integrated and flawless process. | 